Acupoint Selection Based on Meridian Theory in Primary Insomnia of Liver Depression and Spleen Deficiency Type
Launched by CHUANLONG ZHOU · Jan 17, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to treating primary insomnia, specifically for those whose sleep issues are linked to what traditional Chinese medicine describes as "liver depression and spleen deficiency." The researchers are exploring the effects of acupuncture on sleep quality and overall health by carefully selecting specific acupuncture points based on ancient theories and modern medical practices. The trial will measure various factors, including heart rate variability and sleep quality, to see how effective this treatment is in improving sleep for participants.
To be eligible for this study, participants should be between 18 and 40 years old and have been experiencing insomnia for at least two weeks. They should not have insomnia caused by other serious health issues, such as neurological disorders or pregnancy. Participants can expect to receive acupuncture treatment and will be monitored closely for improvements in their sleep and well-being. This trial is currently recruiting participants, offering a potential new way to help those struggling with insomnia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * In line with the diagnostic criteria of insomnia of liver depression and spleen deficiency type in traditional Chinese medicine :
- • In line with the Western diagnostic criteria for insomnia ;
- • 18 ≤ age ≤ 40 years old, male or female ;
- • patients with a course of more than two weeks ; Note: The above criteria must be met for inclusion in this study.
- Exclusion Criteria:
- • Insomnia caused by a variety of organic diseases, neurological or psychiatric disorders
- • Pregnancy, lactation or drug allergy
- • There are more serious primary diseases such as cardiovascular and cerebrovascular diseases, gastrointestinal diseases, endocrine system diseases, or psychiatric patients.
- • Patients with coagulation dysfunction and bleeding tendency.
About Chuanlong Zhou
Chuanlong Zhou is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative studies. With a strong focus on ethical practices and regulatory compliance, Zhou leads a team of experienced professionals who design and implement rigorous clinical trials across various therapeutic areas. By fostering collaboration with healthcare institutions and leveraging cutting-edge methodologies, Chuanlong Zhou aims to contribute valuable insights to the medical community and facilitate the development of novel therapeutics.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported